Treating patients with 177Lutetium PSMA therapy

177Lutetium PSMA is a personalised therapy for patients with advanced prostate cancer.

 

177Lutetium PSMA therapy, or Prostate-Specific Membrane Antigen therapy, is an innovative molecular therapy used to treat advanced prostate cancer. It precisely targets cancerous cells, avoiding damage to surrounding healthy tissue.

How does 177Lutetium PSMA therapy work?

177Lutetium PSMA therapy uses a molecule which attaches itself to the PSMA receptors on the cancer cells. Before it’s given, the PSMA molecule is bound with 177Lutetium, a radioactive substance that damages and destroys prostate cancer cells in a targeted way. The PSMA molecule carries the 177Lutetium straight to the tumour site so the whole body isn’t exposed to radiation.

 

What are the benefits of 177Lutetium PSMA therapy?

This therapy helps:

  • Reduce the size of the tumour and stop it growing
  • Improve the symptoms caused by the tumour
  • Maintain and improve quality of life

After treatment, some patients have a long period of remission and significant improvements in their quality of life.

When would I consider this treatment for my patient?

This therapy is most often used when prostate cancer has metastasised and when other therapies are poorly tolerated or have failed. In certain patients, it appears to be able to produce long term remission.

Before the patient starts treatment they will have a diagnostic GA-68 PSMA PET/CT scan to help identify the location of the cancer. This also helps in staging and planning of treatment.

If the PET/CT scan shows that the patient could benefit from 177Lutetium therapy they will be offered an appointment to discuss what’s involved. We may also ask them to complete a short questionnaire about their general health to help assess whether this treatment is right for them.

Therapy is delivered as an outpatient procedure at our Theranostics suite in Windsor. On the day of treatment the radioactive 177Lutetium will be injected, followed by 1-2 litres of saline. Each cycle is delivered over four hours via a drip inserted into a vein in the arm. The treatment cycle is usually cyclical and normally involves four treatments carried out 6 – 8 weeks apart. Most people have four to six cycles of treatment.

Therapy is personalised according to response and symptoms. Blood tests are carried out before each cycle to check how well things are going.

We will arrange follow up appointments before the patient leaves the department.

Like all cancer treatments, there can be side-effects. These vary from person to person, but may include:

  • Dry mouth
  • Tiredness
  • Mild nausea
  • Loss of appetite

Some patients may produce fewer blood cells than normal for a while. But they’ll be offered regular blood tests to check everything’s OK. We’ll help find ways to reduce and manage any side-effects including medication to reduce any symptoms.

Before the patient starts treatment they will have a diagnostic GA-68 PSMA PET/CT scan to help identify the location of the cancer. This also helps in staging and planning of treatment.

If the PET/CT scan shows that the patient could benefit from 177Lutetium therapy they will be offered an appointment to discuss what’s involved. We may also ask them to complete a short questionnaire about their general health to help assess whether this treatment is right for them.

Therapy is delivered as an outpatient procedure at our Theranostics suite in Windsor. On the day of treatment the radioactive 177Lutetium will be injected, followed by 1-2 litres of saline. Each cycle is delivered over four hours via a drip inserted into a vein in the arm. The treatment cycle is usually cyclical and normally involves four treatments carried out 6 – 8 weeks apart. Most people have four to six cycles of treatment.

Therapy is personalised according to response and symptoms. Blood tests are carried out before each cycle to check how well things are going.

We will arrange follow up appointments before the patient leaves the department.

Like all cancer treatments, there can be side-effects. These vary from person to person, but may include:

  • Dry mouth
  • Tiredness
  • Mild nausea
  • Loss of appetite

Some patients may produce fewer blood cells than normal for a while. But they’ll be offered regular blood tests to check everything’s OK. We’ll help find ways to reduce and manage any side-effects including medication to reduce any symptoms.

Easy Access

Cancer care at GenesisCare may be covered by private medical insurance – we’re recognised by most major insurers. We also offer a range of self-pay packages.

Theranostics is offered at our Windsor centre.

How to refer a patient

Please send a referral/clinic letter to windsor.enquiries@genesiscare.com

For more information

Contact us directly
Tel: 01753 418 444
Email: theranosticsUK@genesiscare.co.uk

Meet Dr Yong Du

Search for a centre near you

Birmingham

Little Aston Hall Drive, Sutton Coldfield, B74 3BF

+44 (0)121 353 3055

Chelmsford

Springfield Cancer Centre, Lawn Lane, Chelmsford, CM1 7GU

+44 (0)1245 987 901

Cromwell Hospital

164-178 Cromwell Rd, Kensington, London SW5 0TU, UK

020 7460 5626

Elstree

Unit 710, Centennial Park, Centennial Avenue, Elstree, Borehamwood, WD6 3SZ

+44 (0)208 236 9040

Guildford

BMI St Martha Oncology Centre, 46 Harvey Road, Guildford, GU1 3LX

+44 (0)1483 806 000

Maidstone

17 Kings Hill Avenue, Kings Hill, West Malling, ME19 4UA

+44 (0)1732 207 000

Milton Keynes

Sunrise Parkway, Linford Wood East, Milton Keynes, MK14 6LS

+44 (0)1908 467 700

Newmarket

The Oaks, Fordham Road, Newmarket, CB8 7XN

+44 (0)1223 907 600

Nottingham

The Park Centre for oncology, Sherwood Lodge Drive, Burntstump Country Park, Nottingham, NG5 8RX

+44 (0)115 966 2250

Oxford

Sandy Lane West, Peters Way, Oxford, OX4 6LB

+44 (0)1865 237 700

Portsmouth

Bartons Road, Havant, PO9 5NA

+44 (0)23 9248 4992

Southampton

Spire Hospital, Chalybeate Close, Southampton, SO16 6UY

+44 (0)238 076 4961

Windsor

69 Alma Road, Windsor, SL4 3HD

+44 (0)1753 418 444